SCHEMBL15051153

SCHEMBL15051153

Cc1cnc(NC(=O)C(C)C)cc1-n1cc(C(N)=O)c(-c2ccccc2Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
JAK2 O60674 8/20 0.40
LIMK1 P53667 1/20 0.40
TSHR P16473 1/20 0.40
TYK2 P29597 4/20 0.39
JAK1 P23458 3/20 0.37
TUBB4A P04350 3/20 0.37
TUBB P07437 3/20 0.37
TUBA3C P0DPH7 3/20 0.37
TUBA1B P68363 3/20 0.37
TUBA4A P68366 3/20 0.37
TUBB4B P68371 3/20 0.37
TUBB3 Q13509 3/20 0.37
TUBB2A Q13885 3/20 0.37
TUBB8 Q3ZCM7 3/20 0.37
TUBA3E Q6PEY2 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15058203 0.89 JAK2 (0.42) JAK2LIMK1TYK2JAK1TUBB4A
SCHEMBL15072379 0.88 TUBB4A (0.41) NPC1SMN1; SMN2ALDH1A1TP53JAK2
SCHEMBL15051441 0.87 SMN1; SMN2 (0.41) RAB9ASMN1; SMN2ALDH1A1JAK2TYK2
SCHEMBL15051427 0.87 ABL1 (0.50) NPC1RAB9ASMN1; SMN2ABL1GSK3B
SCHEMBL31511985 0.83 MAPK8 (0.39) RAB9ASMN1; SMN2ALDH1A1JAK2TYK2
SCHEMBL15051656 0.83 MAPK8 (0.39) RAB9ASMN1; SMN2ALDH1A1JAK2TYK2
SCHEMBL15051386 0.83 JAK2 (0.51) JAK2TYK2JAK1TUBB4ATUBB
SCHEMBL15072396 0.82 TUBB4A (0.38) JAK2TYK2JAK1TUBB4ATUBB
SCHEMBL15072470 0.82 JAK2 (0.37) JAK2TYK2JAK1TUBB4ATUBB
SCHEMBL31512009 0.82 TUBB4A (0.38) JAK2TYK2JAK1TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 NPC1 819/4885RAB9A 119/4885SMN1; SMN2 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.